Literature DB >> 29203593

Loss of p53 compensates osteopenia in murine Mysm1 deficiency.

Melanie Haffner-Luntzer1,2, Anna Kovtun1,2, Verena Fischer1,2, Katja Prystaz1,2, Adelheid Hainzl3, Carsten M Kroeger3, Ioanna Krikki3, Titus J Brinker4,5, Anita Ignatius1,2, Martina Gatzka3.   

Abstract

Histone modifications critically contribute to the epigenetic orchestration of bone homeostasis-in part, by modifying the access of transcription factors to specific genes involved in the osteogenic differentiation process of bone marrow mesenchymal stem cells (MSCs) and osteoblasts. Based on our previous finding that histone H2A deubiquitinase 2A-DUB/Mysm1 interacts with the p53 axis in hematopoiesis and tissue development, we analyzed the molecular basis of the skeletal phenotype of Mysm1-deficient mice and dissected the underlying p53-dependent and -independent mechanisms. Visible morphologic, skeletal deformations of young Mysm1-deficient mice-including a kinked and truncated tail and shortened long bones-were associated with osteopenia of long bones. On the cellular level, Mysm1-deficient primary osteoblasts displayed reduced potential to differentiate into mature osteoblasts, as indicated by decreased expression of osteogenic markers. Reduced osteogenic differentiation capacity of Mysm1-deficient osteoblasts was accompanied by an impaired induction of osteogenic transcription factor Runx2. Osteogenic differentiation of Mysm1-/- MSCs, however, was not compromised in vitro. In line with defective hematopoietic development of Mysm1-deficient mice, Mysm1-/- osteoclasts had reduced resorption activity and were more prone to apoptosis in TUNEL assays. Skeletal alterations and osteopenia of Mysm1-deficient mice were phenotypically completely rescued by simultaneous ablation of p53 in p53-/-Mysm1-/- double-deficient mice-although p53 deficiency did not restore Runx2 expression in Mysm1-/- osteoblasts on the molecular level but, instead, enhanced proliferation and osteogenic differentiation of MSCs. In summary, our results demonstrate novel roles for Mysm1 in osteoblast differentiation and osteoclast formation, resulting in osteopenia in Mysm1-deficient mice that could be abrogated by the loss of p53 from increased osteogenic differentiation of Mysm1-/-p53-/- MSCs.-Haffner-Luntzer, M., Kovtun, A., Fischer, V., Prystaz, K., Hainzl, A., Kroeger, C. M., Krikki, I., Brinker, T. J., Ignatius, A., Gatzka, M. Loss of p53 compensates osteopenia in murine Mysm1 deficiency.

Entities:  

Keywords:  bone; epigenetics; mesenchymal stem cell; osteoblasts

Mesh:

Substances:

Year:  2018        PMID: 29203593     DOI: 10.1096/fj.201700871R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  9 in total

1.  2A-DUB/Mysm1 Regulates Epidermal Development in Part by Suppressing p53-Mediated Programs.

Authors:  Christina Wilms; Ioanna Krikki; Adelheid Hainzl; Sonja Kilo; Marius Alupei; Evgenia Makrantonaki; Maximilian Wagner; Carsten M Kroeger; Titus Josef Brinker; Martina Gatzka
Journal:  Int J Mol Sci       Date:  2018-02-28       Impact factor: 5.923

Review 2.  Deubiquitinase MYSM1 in the Hematopoietic System and beyond: A Current Review.

Authors:  Amanda Fiore; Yue Liang; Yun Hsiao Lin; Jacky Tung; HanChen Wang; David Langlais; Anastasia Nijnik
Journal:  Int J Mol Sci       Date:  2020-04-24       Impact factor: 5.923

Review 3.  Deubiquitinating Enzymes and Bone Remodeling.

Authors:  Yu-Chen Guo; Shi-Wen Zhang; Quan Yuan
Journal:  Stem Cells Int       Date:  2018-07-08       Impact factor: 5.443

4.  MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling.

Authors:  Xu Chen; Wei Wang; Yufang Li; Yi Huo; Han Zhang; Fan Feng; Wenjin Xi; Tianze Zhang; Jinjian Gao; Fan Yang; Siyi Chen; Angang Yang; Tao Wang
Journal:  J Exp Clin Cancer Res       Date:  2021-10-27

Review 5.  Role of histone modification in the occurrence and development of osteoporosis.

Authors:  Pan Sun; Tingrui Huang; Chen Huang; Yongjun Wang; Dezhi Tang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-26       Impact factor: 6.055

6.  Complement receptor C5aR1 on osteoblasts regulates osteoclastogenesis in experimental postmenopausal osteoporosis.

Authors:  Jasmin Maria Bülow; Nikolai Renz; Melanie Haffner-Luntzer; Verena Fischer; Astrid Schoppa; Jan Tuckermann; Jörg Köhl; Markus Huber-Lang; Anita Ignatius
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-30       Impact factor: 6.055

7.  Influence of Menopause on Inflammatory Cytokines during Murine and Human Bone Fracture Healing.

Authors:  Verena Fischer; Miriam Kalbitz; Fabian Müller-Graf; Florian Gebhard; Anita Ignatius; Astrid Liedert; Melanie Haffner-Luntzer
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

8.  Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.

Authors:  Carsten Kroeger; Reinhild Roesler; Sebastian Wiese; Adelheid Hainzl; Martina Vanessa Gatzka
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

9.  Increased Presence of Complement Factors and Mast Cells in Alveolar Bone and Tooth Resorption.

Authors:  Kathrin Luntzer; Ina Lackner; Birte Weber; Yvonne Mödinger; Anita Ignatius; Florian Gebhard; Susann-Yvonne Mihaljevic; Melanie Haffner-Luntzer; Miriam Kalbitz
Journal:  Int J Mol Sci       Date:  2021-03-09       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.